

Commonwealth of Massachusetts MassHealth Drug Utilization Review Program

P.O. Box 2586, Worcester, MA 01613-2586

Fax: (877) 208-7428 **Phone:** (800) 745-7318

Antiretroviral Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Member information						
Last name		MI				
MassHealth member ID #	_Date of birth					
Gender (Check one.) F M	Member's place of residence	ce home nursing facility				
Medication information						
Antiretroviral requested						
Cimduo (lamivudine/tenofovir disoproxil fuma	, — , ,	nivudine/tenofovir disoproxil				
efavirenz/lamivudine/tenofovir disoproxil	fumarate)					
fumarate (600 mg/300 mg/300 mg)		oproxil fumarate tablet > 1 unit/day				
efavirenz/lamivudine/tenofovir disoproxil fumarate (400 mg/300 mg/300 mg)	☐ Tivicay (doit ☐ Trogarzo (ib	utegravir) > 1 unit/day				
nevirapine extended-release	`	fovir disoproxil fumarate) powder ≥				
Rukobia (fostemsavir)	13 years of	, ,				
Selzentry (maraviroc)	, , , , , ,					
Dose, frequency, and duration of medication requested						
Indication (Check all that apply.)						
HIV-1 Current viral load and date						
☐ Chronic Hepatitis B ☐ Other (specify)						
Is this member a referral candidate for care coor	dination? Tyes No					
If yes, MassHealth will offer care coordination services to this member. Please describe which additional						
behavioral health services would be beneficial.						
Section I. Please complete for requests	for tenofovir disoproxil f	umarate tablet > 1 unit/day,				
and Viread powder ≥ 13 years of age.						
Please describe the medical necessity for the agent selected. Please address need for the requested quantity						
(tenofovir disoproxil fumarate tablet), or use in the requested age group (Viread powder), as appropriate.						

PA-22 (Rev. 11/21) over

Sec	tion II. Please complete for Tivicay requests > 1 unit/day.				
	Will the member be taking the requested medication concurrently with carbamazepine, efavirenz,				
fosamprenavir/ritonavir, Aptivus (tipranavir)/ritonavir, or rifampin?					
	☐ Yes. Please document drug name with dose and frequency. ☐ No				
	Drug Dose and Frequency				
2	Does the member have integrase strand transfer inhibitor (INSTI)-associated resistance substitutions or				
۷.	clinically suspected INSTI-resistance?				
	Yes No				
_					
Sec	tion III. Please complete for nevirapine extended-release requests.				
PΙε	ease attach medical records documenting an inadequate response or adverse reaction to nevirapine				
im	mediate-release formulation.				
Sec	tion IV. Please complete for Cimduo, efavirenz/lamivudine/tenofovir disoproxil fumarate,				
	and Temixys requests.				
1.	Please provide clinical rationale for use of the combination product instead of the individual agents.				
•					
2	For members < 18 years of age, please provide member's current weight.				
	For Cimduo and Temixys, will the member be taking the requested medication concurrently with at least one				
٥.					
	other antiretroviral?				
	☐ Yes. Please document drug name with dose and frequency. ☐ No				
	Drug Dose and Frequency				
Sec	tion V. Please complete for Rukobia requests.				
1.	Is the member antiretroviral-experienced with documented historical or baseline resistance, intolerability,				
	and/or contraindication to antiretroviral?				
	☐ Yes. Please document drug name and outcome.* ☐ No				
	Drug				
	Briefly describe details of intolerability, resistance, or other.				
2.	Has the member failed current antiretroviral regimen due to resistance, intolerance, or safety considerations?				
	☐ Yes. Please document drug name and outcome.* ☐ No				
ļ	Drug				
	Briefly describe details of intolerability, resistance, or other.				
_	Will the group has believe the group at all and in a direction and a superior the state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a local content or a state of a superior tracking in a superior tracking in a state of a superior tracking in a superior tracking in a state of a superior tracking in a state of a superior tracking in a state of a superior tracking in a superi				
3.	Will the member be taking the requested medication concurrently with at least one other antiretroviral?				
	Yes. Please document drug name with dose and frequency. No				
	Drug Dose and Frequency				
Sec	tion VI. Please complete for Trogarzo requests.				
	Does the member have resistance to an agent from each of the three classes of antiretrovirals [nucleoside				
••	analog reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI),				
	protease inhibitor (PI)]?				
	☐ Yes. Please document drug names and outcomes.* ☐ No				

NRTI		_ Resistant	Other		
NNRTI			☐ Other		
PI		Resistant	☐ Other		
Briefly describe details of resista	ance or other.				
2. Will the member be taking the re	•	<u>-</u>	other antiretroviral?		
Yes. Please document drug	•	· —			
Drug	Drug Dose and Frequency				
Section VII. Please complete fo	r all requests for non-pref	ferred drug produc	ts if one or more		
preferred drug prod	ducts have been designate	ed for this class of	drugs.		
If one or more preferred drug produ	•	•	• •		
PA for a non-preferred drug produc		essity for prescribing t	he non-preferred drug		
product rather than the preferred drug product.					
					
* Please attach a letter documenting	additional trials as necessary.				
Prescriber information Last name*	First namo*		NAI		
		Individual MH Provider ID			
DEA No.					
Address		State			
E-mail address					
Telephone No.*	Fax No.*				
* Required					
Dung suilsing massidents offerfation					
Prescribing provider's attestation	. •		tified in the Dresewiher		
I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me.					
I certify that the medical necessity i	-		9		
complete, to the best of my knowled	**	•			
prosecution for any falsification, om	•	•			
Prescribing provider's signature (Si	•				
are not acceptable.)	gp.,				
• •					
Printed name of prescribing provide	۶۱	Date			